Communications publiées lors de congrès ou colloques nationaux et internationaux (24)
  1. 17. Van Woensel, M., Wauthoz, N., Rosiere, R., Mathieu, V., Kiss, R., Lefranc, F., Steelant, B., Van Gool, S. W., Mathivet, T., Gerhardt, H., Amighi, K., & De Vleeschouwer, S. (2016). Development of siRNA-loaded Chitosan Nanoparticles targeting Galectin-1 for the Treatment of Glioblastoma Multiforme via Intranasal Administration. Respiratory Drug Delivery 2016. Vol. 3 (pp. 573-578) Respiratory Drug Delivery(17-21/04/2016: Phoenix Arizona).
  2. 18. Wauthoz, N., Hennia, I., Deleers, M., Diez, F., & Amighi, K. (2016). Evaluation of the aerodynamic performance of formoterol dry powder using different capsules for inhalation: hypromellose versus gelatin from Qualicaps and Capsugel. In Abstracts from The Aerosol Society Drug Delivery To the Lung 26: Vol. 29 (pp. 28-29). (3). Journal of Aerosol Medicine and Pulmonary Drug Delivery.
  3. 19. Merlos, R., Wauthoz, N., Belhassan, L., Sebti, T., Traina, K., Vanderbist, F., & Amighi, K. (2015). Scaling-up of an Itraconazole-based Dry Powder for Inhalation from a Lab-sized Büchi Mini Spray Dryer B-290 to a Pilot Mobile Minor Spray Dryer. In R. R. N. Dalby, P. R. Byron, J. Peart, J. D. Suman, P. M. Young, & D. Traini (Eds.), RDD Europe 2015: Book 2 (pp. 441-445) USA: Virginia Commonwealth University.
  4. 20. Rosiere, R., Amighi, K., & Wauthoz, N. (2015). New Dry Powders for Inhalation Containing Chitosan Derivative-Coated Solid Lipid Nanoparticles for Targeted Delivery to Lung Cancer Cells. In R. R. N. Dalby, P. R. Byron, J. Peart, J. D. Suman, P. M. Young, & D. Traini (Eds.), RDD Europe 2015 (pp. 447-452). (book 2). USA: Virginia Commonwealth University.
  5. 21. Wauthoz, N., Hennia, I., Deleers, M., Diez, F., & Amighi, K. (2015). Marketed Formoterol Inhalation Aerosols: A comparative Evaluation to Determine the Place of Capsule-based Dry Powder Inhalers (DPIs). In R. R. N. Dalby, P. R. Byron, J. Peart, J. D. Suman, P. M. Young, & D. Traini (Eds.), RDD Europe 2015 (pp. 453-457). (book 2). USA: Virginia Commonwealth University.
  6. 22. Rosiere, R., Wauthoz, N., Van Antwerpen, P., Gelbcke, M., & Amighi, K. (2014). Development of Folate Receptor-Targeted Nanoparticles Containing Temozolomide for Lung Cancer Therapy by Dry Powder Inhalation. In R. R. N. Dalby, P. R. Byron, J. Peart, S. J. Farr, J. D. Suman, P. M. Young, & D. Traini (Eds.), RDD 2014 Puerto Rico (pp. 609-612). (book 3). USA: Virginia Commonwealth University.
  7. 23. Duret, C., Wauthoz, N., Rosiere, R., Sebti, T., Vanderbist, F., & Amighi, K. (2013). Prophylactic Efficacy of Inhaled Itraconazole-Mannitol Dried Solid Dispersion Against Invasive Pulmonary Aspergillosis. In R. R. N. Dalby, P. R. Byron, J. Peart, J. D. Suman, P. M. Young, & D. Traini (Eds.), RDD Europe 2013 (pp. 383-388). (book 2). USA: Virginia Commonwealth University.
  8. 24. Duret, C., Wauthoz, N., Sebti, T., Vanderbist, F., & Amighi, K. (2012). Itraconazole Nanoparticle-based Dry Powders for Inhalation. In R. R. N. Dalby, P. R. Byron, J. Peart, J. D. Suman, S. J. Farr, & P. M. Young (Eds.), RDD 2012 Arizona (pp. 763-768) USA: Virginia Commonwealth University.
    9.   Participations à des congrès et colloques internationaux (81)
  9. 1. Bui, L., Menchi, E., Blockx, M.-C., Denis, O., Delporte, C., Amighi, K., & Wauthoz, N. (2025). Pharmacokinetic evaluation of controlled release dry powders for inhalation based on budesonide in healthy rats. Poster présenté à la conférence Drug Delivery to the Lungs (35: 2024/12/11 - 2024/12/13: Edinburgh, Scottland).
  10. 2. Bui, L., Olivier, D., Blockx, M.-C., Amighi, K., & Wauthoz, N. (2025). Development of T2-high asthma preclinical model sensitive to inhaled corticosteroids in guinea pigs. Poster présenté à la conférence Fraunhofer seminar « Models of Lung disease » 2025 (23: 19-20 june 2025: Hannover (Germany)).
  11. 3. Guilao, M. G. M., Wauthoz, N., Bah, T. V. B. T., Atchade, C., Traoré, T., Souard, F., Sombie, C. B., Semde, R., & Balde, E. S. (2025). Physicochemical and rheological characterization of new local excipient powders as adjuvant for oral formulations. Abstract session presented at 22 nd Forum Belgian Society of Pharmaceutical Sciences(31 mars 2025: Floreal, la Roche-en-Ardenne)
  12. 4. Abidli, I., Burtea, C., Laurent, S., Crescitelli, E. C., Amighi, K., Wauthoz, N., & Vanderbist, F. (2025). Early biofilm inhibition by N-acetylcysteine and lutein against Pseudomonas aeruginosa PAO1: A potential strategy for cystic fibrosis adjunctive therapy. Abstract session presented at
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Suivant >>